netFormulary NHS
Herefordshire & Worcestershire
Medicines and Prescribing Committee
 Search
 Results

Looking for Adalimumab found 35 matches

Formulary items 3 matches
   
Open monograph to display formulary status BNF Category
  Adalimumab Gastro-intestinal system - Cytokine inhibitors - 01.05.03
  Adalimumab Musculoskeletal and joint diseases - Drugs affecting the immune response - 10.01.03
  Adalimumab Skin - Drugs affecting the immune response - 13.05.03
 


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in subsection NICE TA134: Ankylosing spondylitis - adalimumab, etanercept and infliximab  (10.01.03)
link in drug section NICE TA146 Adalimumab for the treatment of adults with psoriasis (10.01.03)
link in drug section NICE TA146 Adalimumab for the treatment of psoriasis (13.05.03)
link in drug section NICE TA187 Infliximab and adalimumab for the treatment of Crohn’s disease (01.05.03)
link in drug section NICE TA187 Infliximab and adalimumab for the treatment of Crohn’s disease (01.05.03)
link in subsection NICE TA187: Infliximab (review) and adalimumab for the treatment of Crohn’s disease (01.05.03)
link in drug section NICE TA195 Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (10.01.03)
link in drug section NICE TA195 Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (10.01.03)
link in drug section NICE TA195 Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (10.01.03)
link in drug section NICE TA195 Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (10.01.03)
link in subsection NICE TA195: Rheumatoid arthritis - Adalimumab, etanercept, infliximab, rituximab and abatacept  (10.01)
link in drug section NICE TA199 Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (13.05.03)
link in drug section NICE TA199 Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (10.01.03)
link in drug section NICE TA199 Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (10.01.03)
link in drug section NICE TA199 Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (13.05.03)
link in drug section NICE TA199 Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (13.05.03)
link in drug section NICE TA329 Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (10.01.03)
link in drug section NICE TA329 Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (10.01.03)
link in drug section NICE TA329 Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (10.01.03)
link in drug section NICE TA329 Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (01.05.03)
link in drug section NICE TA329 Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (01.05.03)
link in drug section NICE TA373 Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis  (10.01.03)
link in drug section NICE TA373 Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (10.01.03)
link in drug section NICE TA373 Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis  (10.01.03)
link in drug section NICE TA373 Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (10.01.03)
link in drug section NICE TA375 Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA375 Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA375 Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA375 Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA375 Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA375 Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA375 Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)


 

netFormulary